Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jia Jie Biomedical CoROCO:4109 55 Cyclically Adjusted PS Ratio is 1.97 as of Aug. 21, 2026, which is 4% above its 10-year median of 1.90. GuruFocus rates ROCO:4109 with a GF Score™ of 55/100 and a GF Value™ of NT$15.97 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,446 Consumer Packaged Goods companies, Jia Jie Biomedical Co ranks worse than 77.46% on this metric.
The historical rank and industry rank for Jia Jie Biomedical Co's Cyclically Adjusted PS Ratio or its related term are showing as below:
ROCO:4109'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.18 Med: 1.9 Max: 4.66
Current: 1.97
During the past years, Jia Jie Biomedical Co's highest Cyclically Adjusted PS Ratio was 4.66. The lowest was 1.18. And the median was 1.90.
ROCO:4109's Cyclically Adjusted PS Ratio is ranked worse than 77.46% of 1446
companies
in the Consumer Packaged Goods industry
Industry Median: 0.76
vs ROCO:4109: 1.97
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Jia Jie Biomedical Co's adjusted revenue per share data for the three months ended in Jun. 2026 was NT$1.108. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is NT$5.72 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Jia Jie Biomedical Co (ROCO:4109) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Jia Jie Biomedical Co Cyclically Adjusted PS Ratio Related Terms
Jia Jie Biomedical Co Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Jia Jie Biomedical Co's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jia Jie Biomedical Co Cyclically Adjusted PS Ratio Chart
ROCO:4109 vs KHC, GIS: Cyclically Adjusted PS Ratio Comparison
For the Packaged Foods subindustry, Jia Jie Biomedical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jia Jie Biomedical Co Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Jia Jie Biomedical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Jia Jie Biomedical Co's Cyclically Adjusted PS Ratio falls into.
Jia Jie Biomedical Co Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 1.97 mean?
Jia Jie Biomedical Co (ROCO:4109) has a Cyclically Adjusted PS Ratio of 1.97 as of Aug. 21, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Jia Jie Biomedical Co and its competitors. This is near median its historical median of 1.90. Over the past decade, Jia Jie Biomedical Co's Cyclically Adjusted PS Ratio has ranged from 1.18 to 4.66. According to the industry distribution chart, Jia Jie Biomedical Co ranks #1120 out of 1446 companies in the Consumer Packaged Goods industry, placing it in the top 77.5%.
Is Jia Jie Biomedical Co's Cyclically Adjusted PS Ratio too high?
Jia Jie Biomedical Co's current Cyclically Adjusted PS Ratio of 1.97 is near median its 10-year median of 1.90. Over the past 10 years, this metric has ranged from a low of 1.18 to a high of 4.66. The Consumer Packaged Goods industry median Cyclically Adjusted PS Ratio is 0.76. Jia Jie Biomedical Co's value of 1.97 is 159.2% above this industry median. Based on the distribution chart, Jia Jie Biomedical Co ranks #1120 out of 1446 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Jia Jie Biomedical Co has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jia Jie Biomedical Co's Cyclically Adjusted PS Ratio compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Jia Jie Biomedical Co ranks #1120 out of 1446 companies for Cyclically Adjusted PS Ratio. This places Jia Jie Biomedical Co in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 0.76. Jia Jie Biomedical Co's value of 1.97 is 159.2% above this benchmark. Historically, Jia Jie Biomedical Co's own Cyclically Adjusted PS Ratio has ranged from 1.18 to 4.66 over the past decade. While the company's 10-year median is 1.90 vs. the industry median of 0.76, Jia Jie Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Consumer Packaged Goods company?
The median Cyclically Adjusted PS Ratio among Consumer Packaged Goods companies is 0.76, based on 1,446 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jia Jie Biomedical Co's current Cyclically Adjusted PS Ratio of 1.97 is 159.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Jia Jie Biomedical Co and its competitors. For the Consumer Packaged Goods industry, the median Cyclically Adjusted PS Ratio is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jia Jie Biomedical Co's current Cyclically Adjusted PS Ratio is 1.97, which is near median its own 10-year median of 1.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jia Jie Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Jia Jie Biomedical Co (ROCO:4109) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$15.97, compared to a current price of NT$11.25 — trading 29.6% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 1.97, which is near median its 10-year median of 1.90 and 159.2% above the Consumer Packaged Goods industry median of 0.76. Jia Jie Biomedical Co's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Jia Jie Biomedical Co (ROCO:4109), the current Cyclically Adjusted PS Ratio is 1.97 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jia Jie Biomedical Co (ROCO:4109) Overvalued in 2026?
Based on GuruFocus' analysis, Jia Jie Biomedical Co stock appears to be undervalued.
The current stock price of NT$11.25 is trading 29.6% below its estimated GF Value™ of NT$15.97.
GuruFocus considers Jia Jie Biomedical Co to be Significantly Undervalued.
Key valuation signals for ROCO:4109:
Cyclically Adjusted PS Ratio: 1.97 (near median its 10-year median of 1.90)
GF Value™: NT$15.97 vs. price of NT$11.25 (29.6% below fair value)
Industry Position: 159.2% above the Consumer Packaged Goods median (#1120 of 1446)
No single metric tells the full story. See the ROCO:4109 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jia Jie Biomedical Co Ltd is a Taiwan-based company. The Company is engaged in the processing, sale, and trading of softshell turtle food, the Manufacture of Dairy Products, and miscellaneous food manufacturing (e.g., softshell turtle egg powder capsules, enzyme powder, tortoise jelly, softshell turtle oil, and powder capsules). The company is also engaged in the import, export of the aforementioned products, the distribution, bidding, and quotation of aforementioned products for domestic and foreign manufacturers, Wholesale of Nonalcoholic Beverages, candy wholesale, baked food wholesale, supplementary food wholesale, cosmetics wholesale, and sports equipment wholesale.
55GF Score
Get the complete analysis for ROCO:4109
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4109 has been successfully added to your 
